Allogene Therapeutics(NASDAQ) ALLO

Allogene Therapeutics makes ready-to-use cancer treatments from healthy donor cells. These products help doctors treat patients faster than custom-made therapies. The company also develops treatments for people with autoimmune disorders.

What Is in the Pipeline?

• Blood Cancer Candidates: Engineered cells like cema-cel target large B-cell lymphoma and other cancers starting in the immune system.
• Solid Tumor Candidates: Candidate ALLO-316 treats renal cell carcinoma, which is a common type of kidney cancer.
• Autoimmune Disease Pipeline: Candidate ALLO-329 addresses conditions like lupus where the immune system attacks healthy tissue.
• Dagger Technology Platform: Proprietary system designed to help engineered cells survive in the body with less chemotherapy.

Strategic Partners and New Directions

• Closed an underwritten public offering in April 2026 that raised approximately $187.9 million to fund clinical trials.
• Expanded its partnership with Foresight Diagnostics in Feb. 2025 to develop tests for clinical trials in Europe and Australia.
• Acquired rights to develop certain therapies in Europe and the United Kingdom through a May 2024 agreement with Servier.
• Initiated a workforce reduction of approximately 28% in May 2025 to focus resources on core clinical programs.

A New Way to Build Cells

Allogene creates T-cell products using cells from healthy donors rather than the individual patient. This allogeneic approach allows doctors to provide treatments more reliably and at a larger scale than custom methods.

Cash and Spending

• Cash, cash equivalents, and investments totaled $423.6 million as of June 30, 2026.
• Net loss for the three-month period ended June 30, 2026, was $42.7 million.
• Research and development expenses were $62.7 million for the six-month period ended June 30, 2026, down 31% year over year.
• General and administrative expenses were $34.9 million for the six-month period ended June 30, 2026, up 19% year over year.
• Accumulated deficit reached $2.1 billion as of June 30, 2026.

Bottom Line

Allogene has transitioned from early discovery to managing pivotal clinical trials for its lead cancer candidates. The company is now applying its engineering platform to address both oncology and autoimmune disorders.